"The success criteria for artificial intelligence (AI) healthcare is how naturally and continuously it is used within the treatment process. AI is no longer a 'technology to consider adopting'—it has become essential infrastructure where competitiveness suffers if not adopted."
Hyunkyung Shin, Vice President of ACRYL and CEO of Fine Healthcare, is a healthcare management expert with approximately 30 years of experience in medical settings. She diagnoses that healthcare has entered a phase where it is difficult to sustain with a workforce-centered structure. While medical staff labor costs are rising, health insurance reimbursement rates remain stagnant, and patient expectations are increasing. Her approach is to view this problem from a hospital operations perspective rather than a technology perspective.
Vice President Shin said, "AI becomes sustainable only when it solves problems that hospitals repeatedly pay for." This is why Fine Healthcare started with skin-based chronic conditions such as pressure ulcers and burns. While not life-threatening, these are areas with many patients, requiring repetitive management, and where hospitals actually incur costs.
The flagship product 'Skinex Pressure Ulcer' enables stage assessment, treatment guidance, and progress recording with just one photo of the affected area. Its advantage is that it allows evaluation using the same standards even in places like nursing and rehabilitation hospitals that lack specialized personnel or expensive equipment. It is currently being used at Samsung Seoul Hospital, Sejong Chungnam National University Hospital, and other facilities.
Fine Healthcare operates as ACRYL's healthcare subsidiary, handling AI medical devices and platform business, applying ACRYL's data and AI technology to hospital settings. Vice President Shin stated, "ACRYL's listing last year was an event that fundamentally changed the way healthcare AI is developed. Previously, AI development required significant time and cost due to different data structures at each hospital, but now we have a foundation for standardizing hospital data and automatically processing it for AI."
ACRYL's AX infrastructure 'Jonathan' is structured to handle hospital data collection, organization, training, and deployment all at once. It doesn't end with creating a single product—it can expand into multiple clinical, nursing, and administrative areas within a hospital. Hospitals can also shift from being one-time purchasers to utilizing services on a long-term basis.
She said, "The success criteria for medical AI has changed. The key is how naturally patients and medical staff can use it within the treatment process that spans diagnosis, prescription, monitoring, and lifestyle management. Once this structure is established, data accumulates and can serve as the basis for clinical decision-making and insurance and policy discussions."
This year, overseas
market expansion will also begin in earnest. Fine Healthcare has set Southeast
Asia as its first target market. Vice President Shin said, "We are
creating a Southeast Asian model centered on wound care such as pressure ulcers
and burns together with domestic medical device companies. We are designing it
in SaaS and platform formats with reduced equipment dependency so that it can
be used immediately at local hospitals and nursing facilities."
Original Article: